Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Liberalism: Do You Agree We've Had Enough of It? -- Ignore unavailable to you. Want to Upgrade?

To: Kenneth E. Phillipps who wrote (124667)	2/24/2012 1:26:59 PM
From: locogringo	3 Recommendations Read Replies (1) \| Respond to of 224704

This is how one-sided and crazy your lying liberal politcians are........... (can you s'plain this, kenny_troll?) Harry Reid and Senate Democrats Are Holding Up 24 ‘Jobs Bills’ Passed By the House With Gallup’s recent report that the U.S. underemployment rate now stands at a jaw-dropping 19 percent, Speaker John Boehner wants to know why Senate Majority Leader Harry Reid and Senate Democrats have yet to take action on the 24 jobs bills passed by the Republican-led House of Representatives. If the president really wants to get the economy moving again, maybe he’ll pick up the phone and call Senator Reid and ask Senate Democrats to get off their rear ends. biggovernment.com

To: Kenneth E. Phillipps who wrote (124667)	2/25/2012 12:58:36 PM
From: Hope Praytochange	3 Recommendations Respond to of 224704

To: Kenneth E. Phillipps who wrote (124667)	2/25/2012 1:03:10 PM
From: Hope Praytochange	6 Recommendations Respond to of 224704

To: Kenneth E. Phillipps who wrote (124667)	2/25/2012 1:27:43 PM
From: Hope Praytochange	3 Recommendations Respond to of 224704

kennyboy: dont give up HOPE Big pharmaceutical companies have struggled for years to develop a drug that will halt the progression of Alzheimer's disease, a terrible neurological ailment that begins with memory loss and steadily robs patients of brain function, leading to dementia and death. Success would have an enormous societal impact and help to contain the cost of an ever-increasing population of Alzheimer's patients, which number an estimated five million in the U.S.(kennyboy included) -- and 26 million worldwide. It would also have an enormous impact on the health of the pharmaceutical industry, which has struggled to replace revenue lost from patent expirations on some of its biggest drugs and fallen from investor favor. Two compounds, now in late-stage clinical trials, have the potential to do just that. Some think a successful treatment or treatments for Alzheimer's could generate $10 billion to $20 billion in annual revenue. Enlarge Image kennyboy: dont give up HOPE Scott Pollack for Barron's Results from these pivotal trials on solanezumab, developed by Eli Lilly (ticker: LLY), and bapineuzumab, developed by Pfizer (PFE), Elan (ELN) and Johnson & Johnson (JNJ) -- are expected in the third quarter of this year.